KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Accured Expenses (2017 - 2025)

Amneal Pharmaceuticals has reported Change in Accured Expenses over the past 9 years, most recently at $18.6 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $18.6 million for Q4 2025, down 71.96% from a year ago — trailing twelve months through Dec 2025 was $21.3 million (down 90.93% YoY), and the annual figure for FY2025 was $21.3 million, down 90.93%.
  • Change in Accured Expenses for Q4 2025 was $18.6 million at Amneal Pharmaceuticals, down from $69.7 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for AMRX hit a ceiling of $322.7 million in Q2 2022 and a floor of -$150.5 million in Q1 2023.
  • Median Change in Accured Expenses over the past 5 years was $17.3 million (2021), compared with a mean of $11.4 million.
  • Peak annual rise in Change in Accured Expenses hit 1905.87% in 2022, while the deepest fall reached 828.86% in 2022.
  • Amneal Pharmaceuticals' Change in Accured Expenses stood at -$11.1 million in 2021, then crashed by 402.74% to -$55.9 million in 2022, then skyrocketed by 64.63% to -$19.8 million in 2023, then skyrocketed by 435.29% to $66.3 million in 2024, then tumbled by 71.96% to $18.6 million in 2025.
  • The last three reported values for Change in Accured Expenses were $18.6 million (Q4 2025), $69.7 million (Q3 2025), and $45.6 million (Q2 2025) per Business Quant data.